Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: A case report

Journal of Medical Case Reports

Volumn 3, Issue , 2009, Pages

  Goubran, Hadi Alphonse ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE COUNT; HEMATOLOGICAL PARAMETERS; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT;

EID: 73449122254     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-3-7112     Document Type: Article

References (8)

1. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. SG O'Brien F Guilhot RA Larson I Gathmann M Baccarani F Cervantes JJ Cornelissen T Fischer A Hochhaus T Hughes K Lechner JL Nielsen P Rousselot J Reiffers G Saglio J Shepherd B Simonsson A Gratwohl JM Goldman H Kantarjian K Taylor G Verhoef AE Bolton R Capdeville BJ Druker IRIS Investigators, N Engl J Med 2003 348 994 1004 10.1056/NEJMoa022457 12637609 (Pubitemid 36302244)
2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann MW Deininger RT Silver JM Goldman RM Stone F Cervantes A Hochhaus BL Powell JL Gabrilove P Rousselot J Reiffers JJ Cornelissen T Hughes H Agis T Fischer G Verhoef J Shepherd G Saglio A Gratwohl JL Nielsen JP Radich B Simonsson K Taylor M Baccarani C So L Letvak RA Larson IRIS Investigators, N Engl J Med 2006 355 2408 2417 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
3. Cipla Imatib Product Website. 2008 http://www.cipla.com
4. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive, chronic-phase chronic myeloid leukemia after failure of interferon-alpha. HM Kantarjian JE Cortes S O'Brien R Luthra F Giles S Verstovsek S Faderl D Thomas G Garcia-Manero MB Rios J Shan D Jones M Talpaz, Blood 2004 104 1979 1988 10.1182/blood-2004-02-0711 15198956
5. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. JA Zonder P Pemberton H Brandt AN Mohamed CA Schiffer, Clin Cancer Res 2003 9 2092 2097 12796373
6. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. D Martin J Goldman E Olavarria J Apperley, Blood 2003 102 2702 2703 10.1182/blood-2003-06-2042 14504074
7. Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) [abstract]. E Jabbour K Kantarjian E Atallah G Borthakur W Wierda S Faderl S Kornblau J Cortes, Blood 2007 110 1035 10.1182/blood-2007-01-070045 (Pubitemid 350006953)
8. Abbreviated New Drug Application (ANDA) Process for Generic Drugs. US Food and Drug Administration/Center for Drug Evaluation and Research, http://www.fda.gov/cder/regulatory/applications/ANDA.htm